Search - tctmd.com

Displaying 61 - 80 of 696

Sort: Relevancy | Date

News Industry News

CellProthera announces positive Phase I/IIb data for ProtheraCytes® cell therapy in acute myocardial infarction

May 29, 2024

News Conference News EuroPCR 2024

POLMIDES: Hybrid Revascularization Bests CABG For 10-Year Survival

Yael L. Maxwell

May 22, 2024

News Conference News EuroPCR 2024

FFR-Derived Metric Can Identify Focal CAD Best Suited to PCI

Caitlin E. Cox

May 20, 2024

News Conference News EuroPCR 2024

PCI for Multivessel Disease More Cost-effective Than CABG at 3 Years: FAME 3

Yael L. Maxwell

May 17, 2024

News Conference News EuroPCR 2024

ORBITA-2: Angina Phenotype Strongly Predicts PCI Response

Caitlin E. Cox

May 15, 2024

News Conference News EuroPCR 2024

NOW PUBLISHED - Latest TAVI vs Surgery Trial Raises Eyebrows in Aortic Stenosis Plus CAD

Michael O'Riordan

May 14, 2024

News Conference News SCAI 2024

PCI and TAVI Safe, Even When Done at the Same Time: TVT Registry

L.A. McKeown

May 07, 2024

News Daily News

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

Michael O'Riordan

May 06, 2024

News Daily News

Again and Again, Trials Back Short DAPT Post-PCI in ACS: Practice Slow to Shift

Yael L. Maxwell

May 03, 2024

News Features

After DanGer Shock’s Win in AMICS for Impella: What’s Next?

Caitlin E. Cox

May 02, 2024

News Daily News

INOCA May Be at the Root of Angina for Many Long-COVID Patients

Caitlin E. Cox

April 17, 2024

News Conference News ACC 2024

Telemedicine Strategy After MI Scores a Win in TELE-ACS

Caitlin E. Cox

April 12, 2024

News Conference News EHRA 2024

Preventive VT Ablation Before ICD Helps High-risk Ischemic Cardiomyopathy Patients

Todd Neale

April 10, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

News Conference News ACC 2024

EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2

Shelley Wood

April 07, 2024

News Opinion Editor's Corner ACC 2024

What’s Going to Be Hot at ACC 2024

Shelley Wood

April 01, 2024

News Daily News

When Moving From DAPT to Monotherapy After PCI, the P2Y12 Inhibitor Matters

Yael L. Maxwell

March 21, 2024

News Daily News

Real-life Patients Do Well With Intravascular Lithotripsy: Spanish Registry

Caitlin E. Cox

March 01, 2024

News Daily News

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Michael O'Riordan

February 23, 2024

News Daily News

CTO Diagnosed, Now What? European Experts Offer Advice on Revascularization

Caitlin E. Cox

February 09, 2024

Advertisement

CellProthera announces positive Phase I/IIb data for ProtheraCytes® cell therapy in acute myocardial infarction

POLMIDES: Hybrid Revascularization Bests CABG For 10-Year Survival

FFR-Derived Metric Can Identify Focal CAD Best Suited to PCI

PCI for Multivessel Disease More Cost-effective Than CABG at 3 Years: FAME 3

ORBITA-2: Angina Phenotype Strongly Predicts PCI Response

NOW PUBLISHED - Latest TAVI vs Surgery Trial Raises Eyebrows in Aortic Stenosis Plus CAD

PCI and TAVI Safe, Even When Done at the Same Time: TVT Registry

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

Again and Again, Trials Back Short DAPT Post-PCI in ACS: Practice Slow to Shift

After DanGer Shock’s Win in AMICS for Impella: What’s Next?

INOCA May Be at the Root of Angina for Many Long-COVID Patients

Telemedicine Strategy After MI Scores a Win in TELE-ACS

Preventive VT Ablation Before ICD Helps High-risk Ischemic Cardiomyopathy Patients

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2

What’s Going to Be Hot at ACC 2024

When Moving From DAPT to Monotherapy After PCI, the P2Y12 Inhibitor Matters

Real-life Patients Do Well With Intravascular Lithotripsy: Spanish Registry

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

CTO Diagnosed, Now What? European Experts Offer Advice on Revascularization

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content